Medical Use
Welireg is a medication that inhibits hypoxia-inducible factors, used to treat adults with von Hippel-Lindau (VHL) disease who need therapy for associated renal cell carcinoma (RCC), central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, provided they do not require immediate surgery.
Recommended Dosage: The advised dose is 120 mg taken orally once daily, continuing until the disease progresses or unacceptable toxicity occurs. Welireg should be taken at the same time each day and can be consumed with or without food. Patients should swallow the tablets whole, without chewing, crushing, or splitting them.
Missed Dose: If a dose is missed, it should be taken as soon as possible on the same day. The regular dosing schedule should be resumed the following day. Do not take extra tablets to compensate for a missed dose.
Vomiting: If vomiting occurs after taking Welireg, do not retake the dose. Instead, take the next scheduled dose the following day.
Warning & Precautions
Welireg 40 mg tablets can lead to severe anemia, potentially necessitating blood transfusions. It’s crucial to monitor for anemia before starting and periodically during treatment with Welireg. Special attention should be given to patients who are poor metabolizers of UGT2B17 and CYP2C19, as they may experience increased exposure, heightening the risk or severity of anemia.
Erythropoiesis Stimulating Agents (ESAs): The use of ESAs to treat anemia in patients on Belzutifan is not recommended. The safety and effectiveness of ESAs in these patients have not been established.
Hypoxia: Belzutifan can cause serious hypoxia, which may require treatment interruption, supplemental oxygen, or hospitalization. Oxygen saturation should be monitored before starting and periodically during therapy. If oxygen saturation drops during exercise (pulse oximeter <88% or PaO2 ≤55 mm Hg), consider pausing Belzutifan until levels improve, then resume at the same or a reduced dose. For decreased oxygen saturation at rest or if urgent intervention is needed, withhold Belzutifan until resolved, then resume at a lower dose or discontinue. For life-threatening or recurrent symptomatic hypoxia, permanently discontinue treatment. Patients should promptly report any signs or symptoms of hypoxia to their healthcare provider.
Pregnancy: Welireg can cause fetal harm if administered to pregnant women. Verify the pregnancy status of women of reproductive age before starting therapy. Women of reproductive age should use effective non-hormonal contraception during treatment and for 7 days after the final dose, as Welireg can render some hormonal contraceptives ineffective.
Documentation Availability
Documents required to import WELIREG to India?
WELIREG (belzutifan) tablets can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing WELIREG (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the generic name for the trade name drug Welireg®?
The generic name for Welireg® is Belzutifan.
Who manufactures Welireg®?
Welireg® is manufactured by Merck.
Is Welireg® approved by the FDA?
Yes, Welireg® received FDA approval on August 13, 2021.
Where can I find the best price for Welireg® in India?
For the best price on Welireg® (Belzutifan) in India, contact Rx4u team.
What is the dosage form of Welireg®?
Welireg® is available as 40 mg tablets for oral administration.
What are the common side effects of Welireg®?
Common side effects include anemia, fatigue, decreased hemoglobin, increased creatinine, headache, increased glucose, dizziness, and nausea.
How much does Welireg® cost in India?
The cost of Welireg® in India varies. For authentic procurement, you can order on https://rx4u.in/
What are the storage conditions for Welireg®?
Store Welireg® at room temperature between 68°F to 77°F (20°C to 25°C). The bottle contains two desiccant canisters to keep the medication dry. Do not consume the desiccant canisters.
Is it safe to buy Welireg® online from India?
Yes, you can safely purchase Welireg® online from https://rx4u.in/
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
